𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-α

✍ Scribed by Matthew N. Meriggioli; Julie Rowin

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
102 KB
Volume
23
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

✦ Synopsis

Treatment with interferon-␣ (IFN-␣) has been associated with the occurrence of a number of autoimmune disorders. We report a case of chronic inflammatory demyelinating polyneuropathy (CIDP) occurring in a patient with a chronic viral hepatitis C infection who received a novel, longacting form of IFN-␣. After withdrawal of the interferon treatment, this patient responded to a single extended course of plasma exchange that resulted in a complete clinical remission of symptoms without relapse.

📜 SIMILAR VOLUMES

Treatment of chronic inflammatory demyel
Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin
✍ Dr. David R. Cornblath; Vinay Chaudhry; John W. Griffin 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

## Abstract Chronic inflammatory demyelinating polyneuropathy is an immune‐mediated demyelinating peripheral neuropathy usually treated with immunosuppressants. We reviewed our experience treating 15 patients (9 men, 6 women) with intravenous immunoglobulin. Six patients were on other therapies at

Natural leukocyte interferon-α therapy i
Natural leukocyte interferon-α therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-α
✍ Tefferi, Ayalew; Grendahl, Darryl C. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 300 KB

Two patients with chronic-phase chronic granulocytic leukemia initially responded to recombinant interferon a-2a (rlFN-a-2a) but relapsed as a result of development of hightiter neutralizing antibodies to rlFN-a-Sa. Both patients were subsequently treated with natural leukocyte IFN-(Y (IFN-a-n3), an

35-year-old patient with chronic myeloge
35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after α-interferon therapy
✍ Nilesh D. Mehta; Arthur L. Hooberman; Everett E. Vokes; Scott Neeley; Scott Cotl 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

The maculopapular rash recurred in December 1990, associated with fever, severe arthralgias, and headaches. Alpha-interferon was discontinued out of concern that it may be exacerbating the patient's condition. She was admitted to the University of Chicago in January 1991 for evaluation of worsening

Short-term treatment with interferon-α/β
Short-term treatment with interferon-α/β promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis
✍ M. Kariuki Njenga; Michael J. Coenen; Nannette DeCuir; Hung-Yueh Yeh; Moses Rodr 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 346 KB

The mechanisms by which type I interferons (IFN) reduce the rate and severity of exacerbations in multiple sclerosis are unknown. We utilized a model of multiple sclerosis to determine the extent of demyelination and remyelination in Theiler's murine encephalomyelitis virus (TMEV)infected SJL/J mice